Current knowledge and future prospects for the use of HIV protease inhibitors

Drugs

Volumn 51, Issue 5, 1996, Pages 701-712

  Moyle, Graeme ^a   Gazzard, Brian ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; CORE PROTEIN; GAG PROTEIN; INDINAVIR; KYNOSTATIN 272; NELFINAVIR; NUCLEOSIDE ANALOG; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENTIATION; EDITORIAL; ENZYME STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN PROCESSING; VIRUS REPLICATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0029964107     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00001     Document Type: Editorial

References (77)

1. Fischl MA, Richman DD, Greico MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo controlled trial. N Engl J Med 1987; 317: 185-91
2. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus infection: a double-blind, placebo controlled trial. N Engl J Med 1990; 112: 727-37
3. 3 [abstract no. LB 1]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
4. Stephenson J. Other AIDS drug regimens beat AZT alone, reduce clinical progression and mortality. JAMA 1995; 274: 1183-4
5. Moyle G. Resistance to antiretroviral compounds: implications for the clinical management of HIV infection. Immunol Infect Dis 1995; 5: 170-82
6. Keilbaugh SA, Prusotf WH, Simpson MV. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by the anti-HIV 1 dideoxynucleoside analogs. Biochem Pharmacol 1991; 42: R5-8
7. Simpson MV, Chin CD, Keilbaugh SA, et al. Studies on the inhibition of mitochondrial DNA replication by 3́-azido-3́-deoxythymidine and other dideoxynucleoside analogs which inhibit HIV-1 replication. Biochem Pharmacol 1989; 38: 1033-6
8. Moyle G. Influence of emergence of viral resistance on HIV treatment choice. Int J STD AIDS 1995; 6: 225-6
9. Moyle G. HIV treatment choice based on resistance patterns. Intervirology 1994; 37: 367-8
10. LeLacher SF, Simon GI. Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine. J Acquir Immune Defic Syndr 1991; 4: 538-9
11. Back DJ, Hoggard PG, Veal GJ, et al. Intracellular phosphorylation interactions between nucleoside analogues [abstract no. 41]. 5th European Conference on Clinical Aspects and Treatment ot HIV infection: 1945 Sep 26-29; Copenhagen
12. Stretcher BN, Pesce AJ, Frame PT, et al. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994; 8: 763-9
13. Kramer RA, Schaber MD, Skalka AM, et al. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science 1986; 231; 1580-4
14. Kohl NE, Emini EA, Schlief WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90
15. Craig JC, Greif C, Mills JS, et al. Anti-HIV activity of a specific inhibitor of HIV proteinase Ro31-8959 on virus maturation in a chronically infected promonocytic cell line (UI). Antivir Chem Chemother 1991; 2: 188-6
16. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors, Science 1990; 248: 358-61
17. Pettit SC, Michael SF, Swanstrom R. The specificity of HIV-1 proteinase. Perspect Drug Discov Des 1993; 1: 69-83
18. Redshaw S, Inhibitors of HIV proteinase. Exp Opin Invest Drugs 1994; 3: 273-86
19. Szelke M. Chemistry of renin inhibitors. In: Koska V, editor. Aspartic proteinases and their inhibitors, Berlin, New York: De Gruyter, 1985; 421-41
20. Winslow DL, Otto MJ. HIV Protease inhibitors. AIDS 1995; 9 Suppl. A: s183-92
21. Johnson VA, Merrill DP, Chou T-C, et al. Human immunodeficiency virus type-1 (HIV-1) inhibitory interactions between protease inhibitor Ro31-8959 and zidovudine, 2′,3′-dideoxy-cytidine or recombinant interferon-alpha-A against zidovudine-sensitive and -resistant HIV-1 in vitro. J Infect Dis 1992; 166: 1143-6
22. Holmes HC, Mahmoud N, Karpas A, et al. Screening of compounds for activity against HIV: a collaborative study. Antiviral Chem Chemother 1991; 2: 287-93
23. Moyle G. Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996; 5: 155-67
24. Quart BD, Chapman SK, Peterkin J, et al. Phase I safety, tolerance, pharmocokinetics and food effect studies of AG1343-a novel HIV protease inhibitor [abstract no. LB3]. 2nd National Conference on Human Retroviruses and Related Infections: 1994 Jan 29-Feb 2; Washington
25. Vacca JP, Dorsey BD, Schleif WA, et al. An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 1994; 92: 4096-100
26. Markowitz M, Jalil L, Hurley A, et al. Evaluation of the antiviral activity of orally administered ABT-538, an inhibitor of HIV-1 protease [abstract no. 184]. 2nd National Conference on Human Retroviruses and Related Infections: 1994 Jan 29-Feb 2; Washington
27. Painter GR, St Clair MH, DeMiranda P, et al. An overview of the preclinical development of the HIV-protease inhibitor VX-478 (141W94) [abstract no. LB 5]. 2nd National Conference on Human Retroviruses and Related Infections: 1994 Jan 29-Feb 2; Washington
28. Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995; 172: 1238-45
29. Mitsuya H, Weinhold KJ, Furman PA, et al. 3′-azido-3′deoxythymidine (BWA509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenpathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100
30. Langtry HD, Campoli-Richards DM. Zidovudine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989; 37: 408-50
31. Gao WY, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91: 2326-33
32. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118: 681-8
33. Craig JC, Duncan IB, Hockley D, et al. Antiviral properties of R031-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991; 16: 295-305
34. Macalonia SE, Duncan IB, Knight SC. Improved function of dendritic cells exposed in vitro to human immunodeficiency virus type 1 (HIV-1) on treatment with the proteinase inhibitor Ro 31-8959 [abstract no. Po-A25-0601]. IXth International Conference on AIDS: 1993 Jun 6-11; Berlin
35. 1-acid glycoprotein. J Infect Dis 1995; 171:546-51
36. Sommadossi J-P, Schinazi RF, McMillan A, et al. A human serum glycoprotein profoundly affects the antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake [abstract no. LB 4]. 2nd National Conference on Human Retroviruses and Related Infections: 1994 Jan 29-Feb 2; Washington
37. Patick A, Mo H, Markowitz M, et al. In vitro antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of HIV-1 protease [abstract no. 184]. 2nd National Conference on Human Retroviruses and Related Infections: 1994 Jan 29-Feb 2; Washington
38. St Clair MH, Pennington KN, Rooney J, et al. In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the inter-company collaboration protocol. J Acquir Immun Defic Syndr 1995; 10 Suppl. 2: S83-91
39. Craig JC, Duncan IB, Whittaker L, et al. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antivir Chem Chemother 1990; 4: 161-6
40. Patick AK, Boritzki TJ. Combination of HIV-1 protease inhibitor AG1343 with zidovudine, 2′,3′-dideoxycytidine, or didanosine synergistically inhibit acute HIV-1 infection in vitro [abstract no. P8]. Consensus Symposium on Combined Antiviral Therapy: 1995 Jul 25-27; Lisbon
41. Mascolini M. A Lisbon Traviata. J Int Assoc Physician AIDS Care 1995; Sept: 10-22
42. Craig JC, Whittaker LN, Duncan IB, et al. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and zalcitabine with HIV proteinase inhibitor saquinavir (RO 31-8959). Antivir Chem Chemother 1994; 5: 380-6
43. Norbeck D, Kumar G, Marsh K, et al. Ritonavir and saquinavir: potential for two-dimensional synergy between HIV prolease inhibitors [abstract no. LB 7]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20: San Francisco
44. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmocokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstract no. I33]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
45. Cato A, Hsu A. Granneman R, et al. Assessment of the pharmocokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [abstract no. 134]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
46. Kitchen VS, Skinner C, Ariyoshi K, et al. Safety and activity of saquinavir in HIV infection. Lancet 1995; 345: 952-5
47. Delfraissy JF, Serini D, Brun-Vezinet F, et al. A phase I-II dose ranging study of the safety and activity of Ro 31-8959 (HIV-proteinase inhibitor) in previously zidovudine (ZDV)-treated HIV-infected individuals [abstract no. WS-B26-3]. IXth International Conference on AIDS: 1993 Jun 6-11; Berlin
48. Vella S. Update on a proteinase inhibitor. AIDS 1994; 89 Suppl. 3: S25-9
49. Collier AC, Coombs RW, Schoenfeld DA, et al. Extended treatment with saquinavir (SAQ), zidovudine (ZDV) and zalcitabine (ddC) vs SAQ and ZDV vs ddC and ZDV (abstract no. 1731-35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
50. Schapiro JM, Winters MA, Kozal MJ, et al. Saquinavir monotherapy trial: prolonged suppression of viral load and resistance mutations with higher dosage [abstract no. LB 5]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
51. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmocokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33
52. Mathez D, De Truchis P, Gorin I, et al. Ritonavir, AZT, ddC as a triple combination in AIDS patients [abstract no. 285]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington
53. Norbeck D, Hsu A, Granneman R, et al. Virologic and immunologic response to ritonavir (ABT-538), an inhibitor of HIV protease [abstract no. 70). 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
54. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-9
55. Coffin JM. HIV population dynamics in viro: implications for genetic variation, pathogenesis and therapy. Science 1995; 267: 483-9
56. Cameron B, Heath-Chiozzi M, Kravick S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract no. LB6a]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington
57. 3 [abstract no. I172]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
58. Massari F, Staszewski S, Berry P, et al. Adouble-blind, randomized trial of indinavir (MK-639) alone or with zidovudine vs. zidovudine alone in zidovudine naive patients [abstract no. LB 6]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
59. Gulick R, Mellors J, Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC) [abstract no. LB7]. 3rd Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb I; Washington
60. Falloon J, Owen C, Kovacs J, et al. MK-639 (Merck HIV protease inhibitor) with interleukin-2 (IL-2) in HIV [abstract no. 11176]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
61. Markowitz, M, Conant M, Hurley A, et al. Phase I/II dose-finding study of the HIV protease inhibitor AG1343 [abstract no. LB 4]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
62. Moyle G, Youle M, Chapman S, et al. A phase II dose escalation of the Agouron protease inhibitor AG 1343 [abstract no. LB 3]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
63. Movie G, Youle M, Chapman S, et al. A phase I/II dose escalation study of the novel HIV protease inhibitor AG1343 [abstract no. 42]. 5th European Conference on the Clinical Aspects and Treatment of HIV Infection: 1995 Sep 26-29; Copenhagen
64. D'Aquilla RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995; 122:401-8
65. Japour AJ, Welles S, D'Aquilla RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine therapy. J Infect Dis 1995; 171: 1172-9
66. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71
67. Vella S, Butto S, Franco M, et al. Viral load and CD4+ responses during combination therapy with zidovudine and saquinavir: correlation with emergence of viral isolates with reduced sensitivity [abstract no. 43]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
68. Jacobsen H, Yasargil K, Winslow DL, et al. Characterisation of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995; 206: 527-34
69. Jacobsen H, Haenggi M, Ott M, et al. Resistance to saquinavir: update of the genotypic analysis of phase II trials [abstract no. 1174]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
70. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity of saquinavir: an update on genotyping from phase I/II trials [abstract no. 681]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
71. Wilson SI, Phylip LH, Mills JS, et al. Interactions of substrates and inhibitors with escape mutants of HIV-1 proteinase [abstract no. 66]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
72. Mellors JW, McMahon DK, Chodakewitz JA, et al. Correlation between genotypic evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiretroviral effect in treated patients [abstract no. 71]. 4th International Workshop on HIV-Drug Resistance; 1995 Jul 6-9; Sardinia
73. Condra JH, Schlief WA, Blahy OM, et al. Dynamics of acquired HIV-1 clinical resistance to the protease inhibitor MK-639 [abstract no. 72]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
74. Condra JH, Schlief WA, Blahy OM, et al. Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patients [abstract no. 82]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
75. Molla A, Boucher C, Korneyeva M, et al. Evolution of resistance to the protease inhibitor ritonavir (ABT-538) in HIV infected patients [abstract no. 69], 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia
76. Kim EE, Dwyer MD, Thompson JA, et al. Structural analysis of the basis of viral resistance to VX-478 [abstract no. 1278]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17-20; San Francisco
77. Tisdale M, Myers RE, Blair E, et al. In vitro studies support combination therapy with HIV protease inhibitors (abstract no. 61]. 4th International Workshop on HIV-Drug Resistance: 1995 Jul 6-9; Sardinia